Close

Help us reach $1,000,000! Match My Donation

Let's spread the word about Immunotherapy! Click to share this page with your community.
Copy Link

The Clinical Accelerator team actively monitors the rapidly evolving cancer immunotherapy landscape, and we work directly with companies to source innovative agents to be evaluated by our scientific network in our combination clinical trials. As such, the Clinical Accelerator team has established a broad network of biotech and industry partners to enable access to 38 different clinical-stage agents that could be used to support various combination immunotherapy trials. The table below provides the list of the targets organized by different mechanisms of action. 

Targets of 38 Clinical-Stage Agents

  Immunomodulator  
PD-1 PD-L1 CTLA-4
CSF1R IDO1 KIR
FLT3 CD73 TLR-3
4-1BB GITR LAG-3
CD27 ICOS OX40
     
  Cancer Vaccine  
NY-ESO-1 MAGE-C1 MAGE-C2
SURVIVIN TLR-4  
     
  Oncolytic Virus  
  CSF2RA  
     
  Bispecific Antibody  
  CEA  
     
  Targeted Therapy  
STAT3 HER3 MUCIN-1
CD22 ALK AKT
cMET EGFR FGRF1/2/3
MEK-1/2 mTOR PARP
PI3K delta WEE-1 gpNMB
KIT    
     

 

*Immunotherapy results may vary from patient to patient.

Contact Us

Cancer Research Institute | National Headquarters
29 Broadway, 4th Floor | New York, NY 10006-3111

(800) 992-2623(212) 832-9376Staff Directory

Stay Connected with CRI

Follow us
Top